Chonnam Med J.  2007 Dec;43(3):145-149.

Dark Side of Drug-eluting Stent in Contemporary Percutaneous Coronary Intervention

• Rha SW
• Minami Y
• Chen KY
• Jin Z
• Oh DJ

Abstract

Drug-eluting stents (DESs) significantly decrease the rates of restenosis-driven target lesion and vessel revascularization compared with bare metal stents. The sirolimus-eluting stent (SES; Cypher) and the paclitaxel-eluting stent (PES, Taxus) are the two major first generation DESs and have been extensively studied so far. Despite the benefits, questions about safety still remain and we summarize these dark sides of DES, especially focused on some important clinical issues including stent thrombosis, DES fracture and associated restenosis, DES-related endothelial dysfunction or spasm, DES-related aneurysm or late stent malapposition, which might be originated from the coronary arteriopathy associated with DES, and hypersensitivity reactions. Long-term safety and efficacy of these two main DESs should be carefully monitored in every subset of patients.

Keyword

Drug-eluting stent; Complications; Arteriopathy

MeSH Terms

Aneurysm
Drug-Eluting Stents*
Humans
Hypersensitivity
Percutaneous Coronary Intervention*
Spasm
Stents
Thrombosis